Antibody engagement with amyloid-beta does not inhibit [
Alzheimer's disease (AD)
[11C]PiB
amyloid PET
amyloid‐beta
antibody treatment
immunotherapy
Journal
Journal of neurochemistry
ISSN: 1471-4159
Titre abrégé: J Neurochem
Pays: England
ID NLM: 2985190R
Informations de publication
Date de publication:
09 May 2024
09 May 2024
Historique:
revised:
17
04
2024
received:
05
01
2024
accepted:
28
04
2024
medline:
9
5
2024
pubmed:
9
5
2024
entrez:
9
5
2024
Statut:
aheadofprint
Résumé
The elimination of amyloid-beta (Aβ) plaques in Alzheimer's disease patients after treatment with anti-Aβ antibodies such as lecanemab and aducanumab is supported by a substantially decreased signal in amyloid positron emission tomography (PET) imaging. However, this decreased PET signal has not been matched by a similar substantial effect on cognitive function. There may be several reasons for this, including short treatment duration and advanced disease stages among the patients. However, one aspect that has not been investigated, and the subject of this study, is whether antibody engagement with amyloid plaques inhibits the binding of amyloid-PET ligands, leading to a false impression of Aβ removal from the brain. In the present study, tg-ArcSwe mice received three injections of RmAb158, the murine version of lecanemab or phosphate-buffered saline (PBS) before the administration of the amyloid-PET radioligand [
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Gun och Bertil Stohnes Stiftelse
Organisme : Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
Organisme : Stiftelsen för Gamla Tjänarinnor
Organisme : Magnus Bergvalls Stiftelse
Organisme : Åhlén-stiftelsen
Organisme : Hjärnfonden
Organisme : Alzheimerfonden
Organisme : Vetenskapsrådet
ID : 2021-01083
Organisme : Vetenskapsrådet
ID : 2021-03524
Informations de copyright
© 2024 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry.
Références
Alafuzoff, I., & Libard, S. (2020). Mixed brain pathology is the most common cause of cognitive impairment in the elderly. Journal of Alzheimer's Disease, 78(1), 453–465.
Budd Haeberlein, S., Aisen, P. S., Barkhof, F., Chalkias, S., Chen, T., Cohen, S., Dent, G., Hansson, O., Harrison, K., von Hehn, C., Iwatsubo, T., Mallinckrodt, C., Mummery, C. J., Muralidharan, K. K., Nestorov, I., Nisenbaum, L., Rajagovindan, R., Skordos, L., Tian, Y., … Sandrock, A. (2022). Two randomized phase 3 studies of aducanumab in early Alzheimer's disease. The Journal of Prevention of Alzheimer's Disease, 9(2), 197–210.
Castellani, R. J., Shanes, E. D., McCord, M., Reish, N. J., Flanagan, M. E., Mesulam, M. M., & Jamshidi, P. (2023). Neuropathology of anti‐amyloid‐β immunotherapy: A case report. Journal of Alzheimer's Disease, 93(2), 803–813.
Clark, C. M., Schneider, J. A., Bedell, B. J., Beach, T. G., Bilker, W. B., Mintun, M. A., Pontecorvo, M. J., Hefti, F., Carpenter, A. P., Flitter, M. L., Krautkramer, M. J., Kung, H. F., Coleman, R. E., Doraiswamy, P. M., Fleisher, A. S., Sabbagh, M. N., Sadowsky, C. H., Reiman, E. P., Zehntner, S. P., … AV45‐A07 Study Group. (2011). Use of florbetapir‐PET for imaging beta‐amyloid pathology. Journal of the American Medical Association, 305(3), 275–283.
Englund, H., Sehlin, D., Johansson, A. S., Nilsson, L. N., Gellerfors, P., Paulie, S., Lannfelt, L., & Pettersson, F. E. (2007). Sensitive ELISA detection of amyloid‐β protofibrils in biological samples. Journal of Neurochemistry, 103(1), 334–345.
Fang, X. T., Hultqvist, G., Meier, S. R., Antoni, G., Sehlin, D., & Syvanen, S. (2019). High detection sensitivity with antibody‐based PET radioligand for amyloid β in brain. NeuroImage, 184, 881–888.
Fang, X. T., Sehlin, D., Lannfelt, L., Syvanen, S., & Hultqvist, G. (2017). Efficient and inexpensive transient expression of multispecific multivalent antibodies in Expi293 cells. Biological Procedures Online, 19, 11.
Frieg, B., Gremer, L., Heise, H., Willbold, D., & Gohlke, H. (2020). Binding modes of thioflavin T and Congo red to the fibril structure of amyloid‐β (1–42). Chemical Communications, 56(55), 7589–7592.
Gustavsson, T., Metzendorf, N. G., Wik, E., Roshanbin, S., Julku, U., Chourlia, A., Nilsson, P., Andersson, K. G., Laudon, H., Hultqvist, G., Syvänen, S., & Sehlin, D. (2023). Long‐term effects of immunotherapy with a brain penetrating Aβ antibody in a mouse model of Alzheimer's disease. Alzheimer's Research & Therapy, 15(1), 90.
Gustavsson, T., Syvanen, S., O'Callaghan, P., & Sehlin, D. (2020). SPECT imaging of distribution and retention of a brain‐penetrating bispecific amyloid‐β antibody in a mouse model of Alzheimer's disease. Translational Neurodegeneration, 9(1), 37.
Ikonomovic, M. D., Buckley, C. J., Abrahamson, E. E., Kofler, J. K., Mathis, C. A., Klunk, W. E., & Farrar, G. (2020). Post‐mortem analyses of PiB and flutemetamol in diffuse and cored amyloid‐beta plaques in Alzheimer's disease. Acta Neuropathologica, 140(4), 463–476.
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., Debnath, M. L., Hope, C. E., Isanski, B. A., Hamilton, R. L., & DeKosky, S. T. (2008). Post‐mortem correlates of in vivo PiB‐PET amyloid imaging in a typical case of Alzheimer's disease. Brain, 131(Pt 6), 1630–1645.
Liu, E., Schmidt, M. E., Margolin, R., Sperling, R., Koeppe, R., Mason, N. S., Klunk, W. E., Mathis, C. A., Salloway, S., Fox, N. C., Hill, D. L., Les, A. S., Collins, P., Gregg, K. M., di, J., Lu, Y., Tudor, I. C., Wyman, B. T., Booth, K., … Good, S. (2015). Amyloid‐β 11C‐PiB‐PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology, 85(8), 692–700.
Lord, A., Englund, H., Söderberg, L., Tucker, S., Clausen, F., Hillered, L., Gordon, M., Morgan, D., Lannfelt, L., Pettersson, F. E., & Nilsson, L. N. G. (2009). Amyloid‐β protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice. The FEBS Journal, 276(4), 995–1006.
Lord, A., Gumucio, A., Englund, H., Sehlin, D., Sundquist, V. S., Söderberg, L., Möller, C., Gellerfors, P., Lannfelt, L., Pettersson, F. E., & Nilsson, L. N. G. (2009). An amyloid‐β protofibril‐selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease. Neurobiology of Disease, 36(3), 425–434.
Lowe, S. L., Duggan Evans, C., Shcherbinin, S., Cheng, Y. J., Willis, B. A., Gueorguieva, I., Lo, A. C., Fleisher, A. S., Dage, J. L., Ardayfio, P., Aguiar, G., Ishibai, M., Takaichi, G., Chua, L., Mullins, G., & Sims, J. R. (2021). Donanemab (LY3002813) phase 1b study in Alzheimer's disease: Rapid and sustained reduction of brain amyloid measured by florbetapir F18 imaging. The Journal of Prevention of Alzheimer's Disease, 8(4), 414–424.
Magnusson, K., Sehlin, D., Syvänen, S., Svedberg, M. M., Philipson, O., Söderberg, L., Tegerstedt, K., Holmquist, M., Gellerfors, P., Tolmachev, V., Antoni, G., Lannfelt, L., Hall, H., & Nilsson, L. N. G. (2013). Specific uptake of an amyloid‐β protofibril‐binding antibody‐tracer in AβPP transgenic mouse brain. Journal of Alzheimer's Disease, 37(1), 29–40.
Meier, S. R., Sehlin, D., Hultqvist, G., & Syvanen, S. (2021). Pinpointing brain TREM2 levels in two mouse models of Alzheimer's disease. Molecular Imaging and Biology, 23, 665–675.
Meier, S. R., Sehlin, D., Roshanbin, S., Falk, V. L., Saito, T., Saido, T. C., Neumann, U., Rokka, J., Eriksson, J., & Syvänen, S. (2022). 11C‐PiB and 124I‐antibody PET provide differing estimates of brain amyloid‐β after therapeutic intervention. Journal of Nuclear Medicine, 63(2), 302–309.
Meier, S. R., Syvänen, S., Hultqvist, G., Fang, X. T., Roshanbin, S., Lannfelt, L., Neumann, U., & Sehlin, D. (2018). Antibody‐based in vivo PET imaging detects amyloid‐β reduction in Alzheimer transgenic mice after BACE‐1 inhibition. Journal of Nuclear Medicine, 59(12), 1885–1891.
Mishra, S. K., Yamaguchi, Y., Higuchi, M., & Sahara, N. (2021). Pick's tau fibril shows multiple distinct PET probe binding sites: Insights from computational modelling. International Journal of Molecular Sciences, 22(1), 349.
Nelissen, N., van Laere, K., Thurfjell, L., Owenius, R., Vandenbulcke, M., Koole, M., Bormans, G., Brooks, D. J., & Vandenberghe, R. (2009). Phase 1 study of the Pittsburgh compound B derivative 18F‐flutemetamol in healthy volunteers and patients with probable Alzheimer disease. Journal of Nuclear Medicine, 50(8), 1251–1259.
Peccati, F., Pantaleone, S., Riffet, V., Solans‐Monfort, X., Contreras‐García, J., Guallar, V., & Sodupe, M. (2017). Binding of Thioflavin T and related probes to polymorphic models of amyloid‐β fibrils. The Journal of Physical Chemistry. B, 121(38), 8926–8934.
Plowey, E. D., Bussiere, T., Rajagovindan, R., Sebalusky, J., Hamann, S., von Hehn, C., Castrillo‐Viguera, C., Sandrock, A., Budd Haeberlein, S., van Dyck, C. H., & Huttner, A. (2022). Alzheimer disease neuropathology in a patient previously treated with aducanumab. Acta Neuropathologica, 144(1), 143–153.
Rinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., Mathis, C. A., Blennow, K., Barakos, J., Okello, A. A., de LIano, S. R. M., Liu, E., Koller, M., Gregg, K. M., Schenk, D., Black, R., & Grundman, M. (2010). 11C‐PiB PET assessment of change in fibrillar amyloid‐β load in patients with Alzheimer's disease treated with bapineuzumab: A phase 2, double‐blind, placebo‐controlled, ascending‐dose study. Lancet Neurology, 9(4), 363–372.
Rofo, F., Metzendorf, N. G., Saubi, C., Suominen, L., Godec, A., Sehlin, D., Syvänen, S., & Hultqvist, G. (2022). Blood‐brain barrier penetrating neprilysin degrades monomeric amyloid‐β in a mouse model of Alzheimer's disease. Alzheimer's Research & Therapy, 14(1), 180.
Roshanbin, S., Xiong, M., Hultqvist, G., Söderberg, L., Zachrisson, O., Meier, S., Ekmark‐Lewén, S., Bergström, J., Ingelsson, M., Sehlin, D., & Syvänen, S. (2022). In vivo imaging of alpha‐synuclein with antibody‐based PET. Neuropharmacology, 208, 108985.
Rowe, C. C., Ackerman, U., Browne, W., Mulligan, R., Pike, K. L., O'Keefe, G., Tochon‐Danguy, H., Chan, G., Berlangieri, S. U., Jones, G., Dickinson‐Rowe, K. L., Kung, H. P., Zhang, W., Kung, M. P., Skovronsky, D., Dyrks, T., Holl, G., Krause, S., Friebe, M., … Villemagne, V. L. (2008). Imaging of amyloid beta in Alzheimer's disease with 18F‐BAY94‐9172, a novel PET tracer: Proof of mechanism. Lancet Neurology, 7(2), 129–135.
Sehlin, D., Fang, X. T., Cato, L., Antoni, G., Lannfelt, L., & Syvanen, S. (2016). Antibody‐based PET imaging of amyloid β in mouse models of Alzheimer's disease. Nature Communications, 7, 10759.
Sehlin, D., & Syvanen, S. (2019). Engineered antibodies: New possibilities for brain PET? European Journal of Nuclear Medicine and Molecular Imaging, 46(13), 2848–2858.
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., O'Gorman, J., Qian, F., Arastu, M., Li, M., Chollate, S., Brennan, M. S., Quintero‐Monzon, O., Scannevin, R. H., Arnold, H. M., … Sandrock, A. (2016). The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature, 537(7618), 50–56.
Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., Collins, E. C., Solomon, P., Salloway, S., Apostolova, L. G., Hansson, O., Ritchie, C., Brooks, D. A., Mintun, M., Skovronsky, D. M., … Zboch, M. (2023). Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER‐ALZ 2 randomized clinical trial. Journal of the American Medical Association, 330(6), 512–527.
Söderberg, L., Johannesson, M., Nygren, P., Laudon, H., Eriksson, F., Osswald, G., Möller, C., & Lannfelt, L. (2023). Lecanemab, aducanumab, and gantenerumab—Binding profiles to different forms of amyloid‐β might explain efficacy and side effects in clinical trials for Alzheimer's disease. Neurotherapeutics, 20(1), 195–206.
Solbach, C., Uebele, M., Reischl, G., & Machulla, H. J. (2005). Efficient radiosynthesis of carbon‐11 labelled uncharged Thioflavin T derivatives using [11C]methyl triflate for β‐amyloid imaging in Alzheimer's disease with PET. Applied Radiation and Isotopes, 62(4), 591–595.
Swanson, J. D., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J., Lai, R. Y. K., Lannfelt, L., Bradley, H., Rabe, M., Koyama, A., Reyderman, L., Berry, D. A., Berry, S., Gordon, R., Kramer, L. D., & Cummings, J. L. (2021). A randomized, double‐blind, phase 2b proof‐of‐concept clinical trial in early Alzheimer's disease with lecanemab, an anti‐Aβ protofibril antibody. Alzheimer's Research & Therapy, 17(11), 80.
Syvänen, S., Hultqvist, G., Gustavsson, T., Gumucio, A., Laudon, H., Söderberg, L., Ingelsson, M., Lannfelt, L., & Sehlin, D. (2018). Efficient clearance of Aβ protofibrils in AβPP‐transgenic mice treated with a brain‐penetrating bifunctional antibody. Alzheimer's Research & Therapy, 10(1), 49.
Syvänen, S., Meier, S. R., Roshanbin, S., Xiong, M., Faresjö, R., Gustavsson, T., Bonvicini, G., Schlein, E., Aguilar, X., Julku, U., Eriksson, J., & Sehlin, D. (2022). PET imaging in preclinical anti‐Aβ drug development. Pharmaceutical Research, 39(7), 1481–1496.
Tao, Y., Xia, W., Zhao, Q., Xiang, H., Han, C., Zhang, S., Gu, W., Tang, W., Li, Y., Tan, L., Li, D., & Liu, C. (2023). Structural mechanism for specific binding of chemical compounds to amyloid fibrils. Nature Chemical Biology, 19(10), 1235–1245.
Tucker, S., Möller, C., Tegerstedt, K., Lord, A., Laudon, H., Sjödahl, J., Söderberg, L., Spens, E., Sahlin, C., Waara, E. R., Satlin, A., Gellerfors, P., Osswald, G., & Lannfelt, L. (2015). The murine version of BAN2401 (mAb158) selectively reduces amyloid‐β protofibrils in brain and cerebrospinal fluid of tg‐ArcSwe mice. Journal of Alzheimer's Disease, 43(2), 575–588.
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., Froelich, L., Katayama, S., Sabbagh, M., Vellas, B., Watson, D., Dhadda, S., Irizarry, M., Kramer, L. D., & Iwatsubo, T. (2023). Lecanemab in early Alzheimer's disease. The New England Journal of Medicine, 388(1), 9–21.
Ye, L., Velasco, A., Fraser, G., Beach, T. G., Sue, L., Osredkar, T., Libri, V., Spillantini, M. G., Goedert, M., & Lockhart, A. (2008). In vitro high affinity alpha‐synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. Journal of Neurochemistry, 105(4), 1428–1437.
Zielinski, M., Peralta Reyes, F. S., Gremer, L., Schemmert, S., Frieg, B., Schäfer, L. U., Willuweit, A., Donner, L., Elvers, M., Nilsson, L. N. G., Syvänen, S., Sehlin, D., Ingelsson, M., Willbold, D., & Schröder, G. F. (2023). Cryo‐EM of Aβ fibrils from mouse models find tg‐APP(ArcSwe) fibrils resemble those found in patients with sporadic Alzheimer's disease. Nature Neuroscience, 26(12), 2073–2080.